Stockscreener 앱 받기
3.72
6.90%
0.24
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy - MarketBeat
Analysts Issue Forecasts for FBIO FY2025 Earnings - Defense World
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Research Analysts Set Expectations for FBIO FY2025 Earnings - MarketBeat
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Risk Hedge: What are the risks of holding Fortress Biotech IncGap Down & Low Risk Entry Point Guides - baoquankhu1.vn
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States - marketscreener.com
US FDA approves Fortress Bio and Zydus’ treatment for a rare pediatric disease - WHTC
Investors Purchase Large Volume of Fortress Biotech Call Options (NASDAQ:FBIO) - MarketBeat
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease - Reuters
Fortress Biotech Gains FDA Approval for Menkes Treatment - TipRanks
Fortress Biotech (FBIO) Surges After FDA Approval for Zycubo - GuruFocus
Fortress Bio wins FDA nod for Menkes disease drug (FBIO:NASDAQ) - Seeking Alpha
Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo - marketscreener.com
FDA Approves Fortress Biotech's ZYCUBO for Pediatric Menkes Dise - GuruFocus
Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell - marketscreener.com
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire
Fortress Biotech's Subsidiary Nears Key FDA Decision, Shares Rise 3% - Intellectia AI
Trading Systems Reacting to (FBIOP) Volatility - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Up 2.4% – Should You Buy? - Defense World
Will Fortress Biotech Inc.(CNB0) stock rise with strong economyMarket Sentiment Summary & Risk Managed Investment Signals - Улправда
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Aug Rallies: Can Fortress Biotech Inc. stock hit record highs againBond Market & AI Optimized Trade Strategies - Улправда
Will Fortress Biotech Inc. stock benefit from AI adoptionOptions Play & Short-Term Trading Alerts - ulpravda.ru
Can Fortress Biotech Inc. stock hit record highs againMarket Movement Recap & Daily Profit Maximizing Tips - Улправда
How Fortress Biotech Inc. stock compares to industry benchmarksJobs Report & Real-Time Buy Signal Alerts - ulpravda.ru
Will Fortress Biotech Inc. stock outperform international peersJuly 2025 Review & Expert Verified Stock Movement Alerts - Улправда
Is Fortress Biotech Inc.(CNB0) stock testing key supportWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - Улправда
Fortress Biotech amends credit agreement with Oaktree - MSN
Fortress Biotech (NASDAQ: FBIO) reports 13.4% Avenue (ATXI) stake with voting control - Stock Titan
Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc. - 富途牛牛
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Affects Rotational Strategy Timing - Stock Traders Daily
Signal Recap: Will Fortress Biotech Inc stock benefit from AI adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - moha.gov.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Fortress Biotech Inc stockEx-Dividend Date Alerts & High Yield Portfolio Growth - earlytimes.in
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 28% Price Jump - 富途牛牛
Is Fortress Biotech Inc.(CNB0) stock resilient in recession scenarios2025 Market WrapUp & AI Powered Market Trend Analysis - Улправда
Fortress Biotech (NASDAQ: FBIO) registers 600,000 shares for Oaktree resale - Stock Titan
What momentum indicators show for Fortress Biotech Inc. stockJuly 2025 Big Picture & Weekly Setup with High ROI Potential - Улправда
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech’s CUTX-101 NDA resubmission accepted by FDA - MSN
Fortress Biotech (FBIO) files for 600K share offering by selling stockholders - StreetInsider
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Fortress Biotech (Nasdaq: FBIO) resale filing covers 600,000 shares for Oaktree - Stock Titan
Fortress Biotech Amends Credit Agreement with Oaktree - TipRanks
4.73%
0.92%
자본화:
|
볼륨(24시간):